DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Support for the amendments is within the instant application specification.
It is noted that the PTO-326 dated 5/14/2026 incorrectly notified Applicant that claim 37 was allowed, however the office action correctly rejected claim 37. Applicant’s Attorney contacted Examiner on 20 July 2026 regarding the matter. Examiner clarified with Attorney that claim 37 is rejected. Attorney accepted the rejection.
Applicant’s amendment to the claims filed on 8/12/2026 in response to the Non-Final Rejection mailed on 5/14/2026 is acknowledged. This listing of claims replaces all prior listings of claims in the application.
Claims 9-17, 23, 27-33, 35-36, 38 are pending and examined on the merits.
Claim 38 is newly added.
Claims 1-8, 18-22, 24-26, 34, 37 are canceled
Applicant’s remarks filed on 5/14/2026 in response to the Non-Final Rejection mailed on 9/22/2023 have been fully considered and are not deemed persuasive to overcome at least one of the rejections and/or objections as previously applied.
The text of those sections of Title 35 U.S. Code not included in the instant action can be found in the prior Office Action.
Maintained Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The rejection of claims 9-17, 23, 27-33, 35, 36, 38 under 35 U.S.C. 103 as being unpatentable over Fleishman et al. (US 2017/0032079 A1, Date Published: Feb. 2, 2017, cited on PTO-892 filed 5/7/2024) {herein Fleishman} is maintained. The rejection has been modified in view of Applicant’s amendment of claim 9 to recite ‘a ΔΔG value below or equal to threshold value, wherein said ΔΔG threshold value is about +6 R.e.u. or is a value more positive than +6’ (claims 9, 33); the recitation ‘wherein said PSSM threshold value is about -2 or is a value more negative than -2, and a ΔΔG value below or equal to threshold value, wherein said ΔΔG threshold value is about +6 or is a value more positive than +6’ (claim 33); cancellation of claim 37 and new claim 38.
Claims 9-17, 23, 27-33, 35, 36, 38 are drawn to a method for producing a plurality of non-naturally occurring polypeptide variants of an original polypeptide, comprising: (i) providing a template structure that is structurally homologous to the structure of the original polypeptide and optionally subjecting said template structure to energy minimization; (ii) providing a plurality of polypeptide sequences that are each homologous to the amino- acid sequence of the original polypeptide; (iii) within an active/binding site in said template structure identifying substitutable positions and optionally identifying unsubstitutable positions in the amino-acid sequence of the original polypeptide; (iv) for at least 2 of said substitutable residues identifying mutations comprising: a position-specific scoring matrix (PSSM) value above or equal to a threshold value, wherein said PSSM threshold value is below zero; and a ΔΔG value below or equal to threshold value, wherein said ΔΔG threshold value is about +6 R.e.u. or is a value more positive than +6, (v) simultaneously permuting at least two combinations of at least two of said identified mutations, thereby obtaining a list of variants; (vi) enumerating and subjecting each of the variants to energy minimization, and ranking the variants of said list of variants by a stability score based on said energy minimization; and (vii) cloning and expressing the variants with the highest stability score in a protein expression system using a protein expression vector; thereby producing the polypeptide variants in said system.
With respect to claims 9, 27-28, 30, 33, 35, 38, Fleishman teaches a method of producing a modified polypeptide chain starting from an original polypeptide chain and selecting an artificial (non-naturally occurring) protein having improved specific activity (abstract and column 1, para 0012). The method requires assembling a database of qualifying homologous amino acid sequences related to the amino acid sequence of the original polypeptide chain (para 0123). Examiner is interpreting ‘a database of qualifying homologous amino acid sequences’ to be a plurality of polypeptide sequences that are each homologous to the amino acid sequence of the original polypeptide due to the teaching of ‘qualifying homologous amino acid sequences’ by Fleishman which is indicative of more than one amino acid sequence. The position-specific stability scoring is determined for each amino acid alternative, including the original amino acid at that position, by defining a weight fitting shell around the position within which all residues are subjected to a local energy minimization (weight fitting within the weight fitting shell) to determine the lowest energy arrangement for each amino acid within the shell (para 0204). Fleishman further teaches for enzymes catalyzing reactions of substrate molecules in an active site, key residues may be selected within a radius of about 5-8 A around the substrate binding site (para 0179), of which Examiner is interpreting as being within the functional area of the binding/active site. The method includes a step that determines which of the positions in the amino-acid sequence of the original polypeptide chain will be subjected to amino-acid substitution and which amino acid alternatives will be assessed (referred to herein as substitutable positions)(para 0188). Fleishman teaches at least three substitutable positions (figures 2A, 2B, 2C, 2D). At each substitutable position only amino acids having a non-negative PSSM (position-specific scoring matrix) score (i.e. equal to or greater than 0), are subjected to the single position scanning step (para 0201, which is recited in the instant application claim 13 with the recitation of ‘mutations must have a PSSM score equal to or above -2’ with a PSSM above -2 encompassing 0. In claim 9 of the instant Application, Applicant has limited the PSSM threshold value as being below zero with a PSSM value above or equal to a threshold value, of which Fleishman teaches. Applicant’s recitation of ‘a position-specific scoring matrix (PSSM) value above or equal to a threshold value , wherein said PSSM threshold value is below zero’ within claim 9 of the instant application is broad as it encompasses any PSSM threshold value below 0. It is the Examiner’s position that said teaching by Fleishman also reads on the instant application claims 33 and 38 of a PSSM threshold value about -2 or a value more negative than -2 as Fleishman teaches a PSSM negative integer indicates that an amino acid is less probable at the given position than it would have been in a random protein (para 0170). Since it is the goal of Fleischman to create non-naturally occurring polypeptides (para 0097), Fleishman would be motivated to select amino acid position with a negative PSSM, such as a PSSM of -2 or more negative, as doing do would be a clear indication of a non-naturally occurring amino acid substitution. One of ordinary skill in the art would have a reasonable expectation of success to try substituting an amino acid position with a negative PSSM such as the recite -2, as doing so would allow for the synthesis of a non-naturally occurring (artificial) polypeptide, which is the goal of Fleishman (para 0097). Therefore there would be a reasonable expectation of success to arrive at the above invention. Therefore, the above invention would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention.
Fleischman further teaches that the method was implemented using a minimal acceptance threshold of -0.45 r.e.u (∆ ∆G), which meets the claimed limitation of a ΔΔG value below or equal to threshold value, wherein said ΔΔG threshold value is about +6 R.e.u. or is a value more positive than +6 (para 0385), as recited in the instant application claims 9, 13, 33. Thus Flesichman meets the limitation of “below +6 R.e.u.”. Typically, the minimal and thus most permissive (least negative ΔΔG value) acceptance threshold can be determined in a benchmark study (para 0211). As such, it is the examiner’s position that it would be obvious to one of ordinary skill in the art to modify the ‘ΔΔG threshold value’ depending on the protein being mutated. Fleishman further teaches 1-10 alternatives (para 0201). Examiner is interpreting 1-10 alternatives as at least two substitutable residues. Additionally, Fleishman teaches a method for designing a stabilized protein typically results in a modified polypeptide chain having more than 6 amino-acid substitutions with respect to the original (wildtype) polypeptide chain which have diverse physiochemical properties in various combinations (para 0094). Fleishman further teaches a combinatorial design of the entire amino acid sequence of the modified polypeptide chain, wherein numerous amino acid substitutions are simultaneously introduced to the sequence of the original polypeptide chain (para 0214). Examiner is interpreting said recitation to be synonymous to ‘simultaneously permuting combinations of said identified mutations’ as the amino acids are being simultaneously ‘permuted/substituted’ or subjected to a process of alteration in combinations. At least two of the amino acids of the substituted amino acids in the designed protein interact with one another such that the interaction stabilizes the modified protein (para 0278). The combinatorial step yields a final variant with a combination of mutations that are all compatible with one another (para 0215). A position-specific stability score is given to each of the allowed amino acid alternatives at each substitutable position (para 0189). The position-specific stability scoring is determined for each amino acid alternative, including the original amino acid at that position, by defining a weight fitting shell around the position within which all residues are subjected to a local energy minimization (weight fitting within the weight fitting shell) to determine the lowest energy arrangement for each amino acid within the shell (para 0204). Examiner is interpreting the recitations of ‘determine the lowest energy arrangement for each amino acid within the shell’ to be ranking the variants by a stability score and providing a list of variants. Three exemplary variants (stabilized PTE variants) were cloned into an expression vector and cell (para 0409). Examiner is interpreting ‘exemplary variants’ to be synonymous to those variants with the highest stability score. The polypeptide variants were purified (para 0409). The PTE variants displayed increased levels of soluble, functional enzyme compared to the reference protein (para 0412). Additionally, said variants exhibited increased metal affinity (para 0412). Examiner is interpreting an increase in metal affinity to be an increase in specific activity because metal binding can facilitate enzymatic activity.
With respect to claim 10, Fleishman teaches a method wherein a variant polypeptide exhibited a marked increase in metal affinity compared to other variants (para 0412). Examiner is interpreting the binding affinity of the metal to the protein variants to be synonymous to a ligand-binding score since the metal was shown by Fleishman to bind the protein variants differently, based on their designs. Said protein variants were selected based on their metal binding affinity (table 5).
With respect to claim 11, Fleishman teaches a position-specific stability score is given to each
of the allowed amino acid alternatives at each substitutable position (para 0189). A comprehensive list of amino acid alternatives that have a position-specific stability score below -0.45 r.e.u. (i.e., are predicted to be stabilizing) is referred to herein as the "sequence space" (para 0189). In addition, the rate at which free energy is changed is correlated to a stability score, which is referred to herein as "a position-specific stability scoring (para 0197). Polypeptide variants with the highest stability scores were selected (table 4).
With respect to claim 12, Fleishman teaches redundant sequences are clustered into a single
representative sequence (para 0127). The clustering is carried out with a threshold of 0.97, meaning that all sequences that share at least 97% identity among themselves are clustered into a single representative sequence that is the average of all the sequences contributing to the cluster (para 0127).
With respect to claim 13, Fleishman teaches at each substitutable position only amino acids having a non-negative PSSM score (i.e. equal to or greater than 0), are subjected to the single position scanning step (para 0201). Examiner is interpreting said recitation as identifying all mutation comprising a PSSM value above -2, which is the claimed PSSM threshold. Furthermore, the method was implemented using a minimal acceptance threshold of -0.45 r.e.u; however, if an overly-permissive acceptance threshold of zero were used, the method would have correctly predicted four additional stabilizing mutations (overall 47% true positives), and would have also predicted eight additional
false-positives (i.e., overall 96% true negatives). Examiner is interpreting a threshold of -0.45 r.e.u and an overly-permissive acceptance threshold to be a threshold below +6 r.e.u.
With respect to claim 14, Fleishman teaches a stabilized variant, which is a template of the original polypeptide (table 5, para 0409).
With respect to claim 15, Fleishman teaches a method wherein the amino acid sequence of the original polypeptide chain has been threaded thereon and subjected to weighted fitting to afford energy minimization (para 0109). Examiner is interpreting the original polypeptide to be the template.
With respect to claims 16 and 23, Fleishman teaches a method wherein the template structure is of a homologous protein and the query sequence is first threaded on the protein's template structure using well established computational procedures (para 0120). The structural information is a set of atomic coordinates of the original polypeptide chain (para 0109). This set of atomic coordinates is referred to herein as the "template structure" (para 0109). The template structure is a computationally generated structure based on a crystal structure of a close homolog (more than 40-60% identity) of the original polypeptide chain, wherein the amino acid sequence of the original polypeptide chain has been threaded thereon and subjected to weighted fitting to afford energy minimization thereof (para 0109).
With respect to claim 17, Fleishman teaches a method wherein the energy minimization may include iterations of rotamer sampling (repacking) followed by side chain and backbone minimization. (para 0118).
With respect to claim 29, Fleishman teaches a method wherein the position-specific stability scoring is determined for each amino acid alternative, including the original amino acid at that position, by defining a weight fitting shell around the position within which all residues are subjected to a local energy minimization (weight fitting within the weight fitting shell) to determine the lowest energy arrangement for each amino acid within the shell (para 0204). Examiner is interpreting the recitations of ‘determine the lowest energy arrangement for each amino acid within the shell’ to be ranking the variants by a stability score and providing a list of variants. Three exemplary variants (stabilized PTE variants) were cloned into an expression vector and cell (para 0396). Examiner is interpreting ‘exemplary variants’ to be synonymous to those variants with the highest stability score.
With respect to claims 31-32, Fleishman teaches a method wherein combinatorial design of the entire amino acid sequence of the modified polypeptide chain, wherein numerous amino acid substitutions are simultaneously introduced to the sequence of the original polypeptide chain (para 0214). Examiner is interpreting said recitation to be synonymous to ‘simultaneously permuting combinations of said identified mutations’ as the amino acids are being simultaneously ‘permuted/substituted’ in combinations. At least two of the amino acids of the substituted amino acids in the designed protein interact with one another such that the interaction stabilizes the modified protein (para 0278). The combinatorial step yields a final variant with a combination of mutations that are all compatible with one another (para 0215). A position-specific stability score is given to each of the allowed amino acid alternatives at each substitutable position (para 0189). The position-specific stability scoring is determined for each amino acid alternative, including the original amino acid at that position, by defining a weight fitting shell around the position within which all residues are subjected to a local energy minimization (weight fitting within the weight fitting shell) to determine the lowest energy arrangement for each amino acid within the shell (para 0204). Examiner is interpreting the recitations of ‘determine the lowest energy arrangement for each amino acid within the shell’ to be ranking the variants by a stability score and providing a list of variants. Three exemplary variants (stabilized PTE variants) were cloned into an expression vector and cell (para 0409). Examiner is interpreting ‘exemplary variants’ to be synonymous to those variants with the highest stability score. All stability scores of the variants (ΔΔG) are below -0.45 (para 0189). However, if an overly-permissive acceptance threshold
of zero were used, the method would have correctly predicted four additional stabilizing mutations (overall 47% true positives), and would have also predicted eight additional false-positives (i.e., overall 96% true negatives) (para 0385). PSSM values are at least 0 (para 0024), which is above the recited PSSM threshold value of below 0. Fleishman teaches for enzymes catalyzing reactions of substrate molecules in an active site, key residues may be selected within a radius of about 5-8 A around the substrate binding site (para 0179), of which Examiner is interpreting as being within the functional area of the binding/active site. The method includes a step that determines which of the positions in the amino-acid sequence of the original polypeptide chain will be subjected to amino-acid substitution and which amino acid alternatives will be assessed (referred to herein as substitutable positions), and in which positions in the amino acid sequence of the original polypeptide chain the amino-acid will not be subjected to amino-acid substitution (para 0188). It is the Examiner’s position that all mutations comprising a PSSM value above or equal to the claims PSSM threshold, including those within the first shell and active/binding site. In addition, only amino acid alternatives that have ΔΔG values lower than this acceptance threshold will be permitted into the next step of the method (para 0209). Fleishman teaches a minimal acceptance threshold of -0.45 r.e.u ∆ ∆G (para 0211) of which Examiner is interpreting as being a ΔΔG value below a threshold value that below +6 as recited in the instant application claim 9. Since said minimal threshold value is below the claimed threshold of +6, Examiner is interpreting said teaching to read on claim 28, ‘a ΔΔG value below or equal to said ΔΔG threshold.’ Fleishman further teaches 1-10 alternatives (para 0201). Examiner is interpreting ‘1-10 alternatives’ as at least two substitutable residues.
With respect to claim 36, Fleishman teaches specific activity of the designed protein being higher than a specific activity of the original peptide (claim 1). Fleishman further teaches a method for designing and selecting a protein having a stabilized structure compared to a corresponding wild type
protein, and proteins having at least six amino acid substitutions with respect to a corresponding wild type protein, designed for improved thermal stability, improved specific activity (abstract).
Before the effective filing date of the claimed invention, it would have been obvious to one of ordinary skill in the art to try a ΔΔG threshold value below +6 as Fleishman teaches if an overly-permissive acceptance threshold of zero were used (which is below +6), the method would have correctly predicted four additional stabilizing mutations (overall 47% true positives) (para 0385).
One of ordinary skill in the art would have had a reasonable expectation of success, a reasonable level of predictability, and would be motivated to try a ΔΔG threshold value below +6 as Fleishman teaches 4 additional stabilizing mutations would have been identified if the ΔΔG threshold value were changed from -0.45 r.e.u to 0 r.e.u. As such, it would be obvious to one of ordinary skill in the art to try a threshold value below +6 as doing so may result in additional stabilizing mutations being identified. Especially since Fleishman teaches the invention, is not limited to any particular minimal acceptance threshold, and other values are contemplated within the scope of the invention (para 0211). It is the Examiner position that a threshold value below +6 would be within the scope of the invention taught by Fleishman since Fleishman teaches the unexpected result of 4 additional stabilizing mutations at a threshold value above -0.45 r.e.u. Additionally, MPEP 2144.05 states"[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955) (MPEP 2144.05 IIA)." One of ordinary skill would desire to optimize the acceptance threshold of the protein depending on the particular application. It would be routine for one to arrive at a ΔΔG threshold value below +6 for the application they intend on using the polypeptides. Therefore, the above invention would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention.
RESPONSE TO REMARKS:
Applicant contends that it must be pointed out that in the Office Action Summary it states that previous Claim 37 is allowed. Claim 37, however, is included in the obviousness rejection, though no reason is given for this rejection. Applicant reached out to the Examiner and was told that Claim 37 is rejected on the same grounds as the rest of the claims, but Applicant believes this is an error. Applicant contends that in the Office Action's closing statement it is written "Examiner contends that Applicant's claim limitations recite a AAG threshold value as small as 0.1. Examiner suggests that Applicant recite a specific AAG threshold value that is above 0." This is exactly what was in previous claim 37 and is now in instant claim 9. The ΔΔG threshold is recited in claim 9 to be "below or equal to a threshold value wherein ΔΔG threshold value is about +6 R.e.u. or is a value more positive than +6". Thus, instant claim 9 recites a specific threshold value that is not close to zero Plus 6 is significantly more than zero. A skilled artisan would therefore understand that substantially destabilizing mutations are being included, which is certainly not disclosed in Fleishman which teaches away from destabilizing/deleterious mutations. The recitation that the threshold can be even more positive than +6 only expands to even more destabilizing thresholds which certainly is non-obvious over Fleishman. Applicant contends that the instant claim 9 does exactly what was requested in the Office Action. It recites a specific positive threshold that is not close to zero. The +6 threshold was the threshold actually used in the Examples section of the instant application. Thus, claim 9 is non-obvious.
The argument is not persuasive. Examiner contends that the recitation ‘a ΔΔG value below or equal to threshold value, wherein said ΔΔG threshold value is about +6 R.e.u. or is a value more positive than +6’ within the instant application claims 9, 33 plainly means a ΔΔG value below +6 R.e.u., of which Fleischman teaches with a minimal acceptance threshold of -0.45 r.e.u (∆ ∆G) (para 0385). Therefore, the recitation of a ΔΔG value below a threshold value of +6 encompasses the taught ΔΔG threshold value of -0.45. Regarding Examiner’s grammatical mistake with including claim 37 on the PTO-326 form as allowable, Examiner thanks Applicant for acknowledging the mistake and acceptance of the correction of claim 37 being not allowed during the Examiner’s Interview with Roy Gross, Reg # 63,524, on 20 July 2026. In addition, regarding Applicant’s argument that the ΔΔG threshold recited in claim 9 is "below or equal to a threshold value wherein ΔΔG threshold value is about +6 R.e.u. or is a value more positive than +6" is slightly confusing as Applicant is claiming a ΔΔG value below or equal to +6 and then claiming a value more position that +6. Furthermore, Applicant’s argument that the threshold can be even more positive than +6 only expands to even more destabilizing thresholds is contradictory to Applicant’s instant application.
Applicant contends that new claim 38 also provides a specific value for the PSSM threshold (-2 or lower). This threshold is also not close to zero and certainly results in the inclusion of deleterious mutations. Further, it is the threshold actually used in the Examples section of the instant application.
The argument is not persuasive. Examiner contends that since it is the goal of Fleischman to create non-naturally occurring polypeptides (para 0097), Fleishman would be motivated to select amino acid position with a negative PSSM, such as the recited PSSM of -2 or more negative (instant application claims 9, 33, as doing do would be a clear indication of a non-naturally occurring amino acid substitution. One of ordinary skill in the art would have a reasonable expectation of success to try substituting an amino acid position with a negative PSSM such as the recite -2 or more negative, as doing so would allow for the synthesis of a non-naturally occurring (artificial) polypeptide, which is the goal of Fleishman (para 0097). Therefore there would be a reasonable expectation of success to arrive at the above invention. Therefore, the above invention would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention.
Conclusion
Status of Claims
Claims 9-17, 23, 27-33, 35-36, 38 are pending.
Claims 1-8, 18-22, 24-26, 34, 37 are canceled.
Claims 9-17, 23, 27-33, 35-36, 38 are rejected.
No claims are in conditions for allowance.
THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to ERICA NICOLE JONES-FOSTER whose telephone number is (571)270-0360. The examiner can normally be reached mf 7:30a - 4:30p.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Manjunath Rao can be reached at 571-272-0939. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/ERICA NICOLE JONES-FOSTER/Examiner, Art Unit 1656
/MANJUNATH N RAO/Supervisory Patent Examiner, Art Unit 1656